Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction Insights From REVIVED-BCIS2

被引:3
|
作者
Ryan, Matthew [1 ,2 ]
Taylor, Dylan [3 ]
Dodd, Matthew [3 ]
Spertus, John A. [4 ]
Kosiborod, Mikhail N. [4 ]
Shaukat, Aadil [5 ]
Docherty, Kieran F. [6 ,7 ]
Clayton, Tim [3 ]
Perera, Divaka [2 ]
Petrie, Mark C. [6 ]
机构
[1] Kings Coll London, British Heart Fdn Ctr Res Excellence, Sch Cardiovasc & Metab Med & Sci, London, England
[2] Guys & St Thomas NHS Fdn Trust, London, England
[3] London Sch Hyg & Trop Med, Clin Trials Unit, London, England
[4] Dept City, Platte City, MO USA
[5] Golden Jubilee Natl Hosp, West Scotland Heart & Lung Ctr, Clydebank, England
[6] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
[7] Glasgow Royal Infirm, Dept Cardiol, Glasgow, Scotland
关键词
coronary artery disease; left ventricular dysfunction; percutaneous coronary intervention; quality of life; randomized trial; win ratio; QUALITY-OF-LIFE; CITY CARDIOMYOPATHY QUESTIONNAIRE; CLINICAL-TRIALS; REVASCULARIZATION; SURGERY;
D O I
10.1016/j.jchf.2024.03.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND In the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial, percutaneous coronary intervention (PCI) did not reduce the incidence of death or hospitalization for heart failure (HHF). OBJECTIVES This prespecified secondary analysis investigated the effect of PCI on health status measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) combined with the primary outcome in a win ratio. METHODS Participants with severe ischemic left ventricular dysfunction were randomized to either PCI in addition to optimal medical therapy (OMT) (PCI) or OMT alone (OMT). The primary outcome was a hierarchical composite of all-cause death, HHF, and KCCQ-Overall Summary Score (OSS) at 24 months analyzed using the unmatched win ratio. The key secondary endpoint was a KCCQ-OSS responder analysis. RESULTS A total of 347 participants were randomized to PCI and 353 to OMT. Median age was 70.0 years (Q1-Q3: 63.376.1 years). Mean left ventricular ejection fraction was 27.0 f 6.7%. PCI did not improve the primary endpoint (win ratio for PCI vs OMT: 1.05; 95% CI: 0.88-1.26; P = 0.58). PCI resulted in more KCCQ-OSS responders than OMT at 6 months (54.1% vs 40.7%; OR: 1.96; 95% CI: 1.41-2.71; P < 0.001) and fewer deteriorators (25.2% vs 31.4%; OR: 0.69; 95% CI: 0.47-1.00; P = 0.048). PCI did not impact KCCQ-OSS responders or deteriorators at 12 or 24 months. CONCLUSIONS PCI did not improve the hierarchical composite of death, HHF, and health status at 2 years. PCI improved KCCQ-OSS at 6 months, but this benefit was not sustained to 1- or 2-year follow-up. (Revacularization for Ischemic Ventricular Dysfunction [REVIVED-BCIS2]; NCT01920048) (JACC Heart Fail. 2024;12:1553-15 62) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:1553 / 1562
页数:10
相关论文
共 50 条
  • [1] Post-ischemic left ventricular dysfunction: coronary angioplasty and the solution? The REVIVED-BCIS2 study
    De Luca, Leonardo
    Fanale, Valerio
    Gabrielli, Domenico
    GIORNALE ITALIANO DI CARDIOLOGIA, 2023, 24 (04) : 255 - 259
  • [2] Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial
    Chivardi, Carlos
    Morgan, Holly
    Sculpher, Mark J.
    Clayton, Tim
    Evans, Richard
    Dodd, Matthew
    Petrie, Mark
    Rinaldi, Christopher A.
    O'Kane, Peter
    Brown, Louise
    Perera, Divaka
    Saramago, Pedro
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2024, 17 (01): : E010533
  • [3] Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial
    Perera, Divaka
    Morgan, Holly P.
    Ryan, Matthew
    Dodd, Matthew
    Clayton, Tim
    O'Kane, Peter D.
    Greenwood, John P.
    Walsh, Simon J.
    Weerackody, Roshan
    Mcdiarmid, Adam
    Amin-Youssef, George
    Strange, Julian
    Modi, Bhavik
    Lockie, Timothy
    Hogrefe, Kai
    Ahmed, Fozia Z.
    Behan, Miles
    Jenkins, Nicholas
    Abdelaal, Eltigani
    Anderson, Michelle
    Watkins, Stuart
    Evans, Richard
    Rinaldi, Christopher A.
    Petrie, Mark C.
    CIRCULATION, 2023, 148 (11) : 862 - 871
  • [4] Prognostic impact of inducible ischaemia in ischaemic left ventricular dysfunction: the REVIVED-BCIS2 trial
    Morgan, Holly
    Nazir, Muhummad Sohaib
    Wa, Matthew E. Li Kam
    Mccann, Gerry P.
    Greenwood, John P.
    Mcdiarmid, Adam K.
    Dodd, Matthew
    Ryan, Matthew
    Perera, Divaka
    Chiribiri, Amedeo
    EUROPEAN HEART JOURNAL, 2024, 46 (05) : 487 - 490
  • [5] Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial Percutaneous Coronary Intervention for Ischemic Cardiomyopathy
    Perera, Divaka
    Clayton, Tim
    Petrie, Mark C.
    Greenwood, John P.
    O'Kane, Peter D.
    Evans, Richard
    Sculpher, Mark
    Mcdonagh, Theresa
    Gershlick, Anthony
    de Belder, Mark
    Redwood, Simon
    Carr-White, Gerald
    Marber, Michael
    JACC-HEART FAILURE, 2018, 6 (06) : 517 - 526
  • [6] Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial
    Perera, Divaka
    Ryan, Matthew
    Morgan, Holly P.
    Greenwood, John P.
    Petrie, Mark C.
    Dodd, Matthew
    Weerackody, Roshan
    O'Kane, Peter D.
    Masci, Pier Giorgio
    Nazir, Muhummad Sohaib
    Papachristidis, Alexandros
    Chahal, Navtej
    Khattar, Rajdeep
    Ezad, Saad M.
    Kapetanakis, Stam
    Dixon, Lana J.
    De Silva, Kalpa
    McDiarmid, Adam K.
    Marber, Michael S.
    McDonagh, Theresa
    McCann, Gerry P.
    Clayton, Timc.
    Senior, Roxy
    Chiribiri, Amedeo
    JAMA CARDIOLOGY, 2023, 8 (12) : 1154 - 1161
  • [7] RADIATION EXPOSURE DURING PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE REVIVED-BCIS2 TRIAL
    Burra, Vyas
    Perera, Divaka
    Pavlidis, Antonis
    Morgan, Holly
    Ryan, Matthew
    HEART, 2023, 109 : A61 - A62
  • [8] REVISITING THE UTILITY OF LATE GADOLINIUM ENHANCEMENT TO PREDICT SEGMENTAL RECOVERY IN ISCHEMIC VENTRICULAR DYSFUNCTION: SECONDARY ANALYSIS OF THE REVIVED-BCIS2 RANDOMISED TRIAL
    Ryan, Matthew
    Morgan, Holly
    Nazir, Sohaib
    Masci, Pier Giorgio
    Dodd, Matt
    Mancio, Jennifer
    Alskaf, Ebraham
    McDiarmid, Adam Kenneth
    Kapetanakis, Stamatis
    McCann, Gerry
    Greenwood, John P.
    Clayton, Tim
    Chiribiri, Amedeo
    Perera, Divaka
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1358 - 1358
  • [9] EARLY IMPROVEMENT IN QUALITY OF LIFE WITH PERCUTANEOUS CORONARY INTERVENTION VERSUS MEDICAL THERAPY IN SEVERE ISCHEMIC VENTRICULAR DYSFUNCTION: DATA FROM THE REVIVED-BCIS2 RANDOMIZED TRIAL
    Ryan, Matthew
    Taylor, Dylan
    Dodd, Matt
    Clayton, Tim
    Kosiborod, Mikhail
    Spertus, John A.
    Perera, Divaka
    Petrie, Mark
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 381 - 381
  • [10] PCI for Ischemic Left Ventricular Dysfunction Reply
    Perera, Divaka
    Ryan, Matthew
    O'Kane, Peter D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (02): : 188 - 189